Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00086944
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00086892
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Non-small Cell Lung Cancer Study US75 (Z-PACT)
- Conditions
- Interventions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT00086268
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Advocate Illinois Masonic Medical Center Creticos Cancer Center, Chicago, Illinois, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Registration Number
- NCT00004202
- Locations
- 🇺🇸
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Cancer Center of Albany Medical Center, Albany, New York, United States
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 57
- Registration Number
- NCT00003127
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Providence Hospital - Southfield, Southfield, Michigan, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 480
- Registration Number
- NCT00003317
- Locations
- 🇺🇸
Rapid City Regional Hospital, Rapid City, South Dakota, United States
🇺🇸CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
🇺🇸CCOP - Duluth, Duluth, Minnesota, United States
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006235
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00003206
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 36
- Registration Number
- NCT00003860
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg, Strasbourg, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
- Conditions
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mesnaDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT00002740
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.